Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BTTX Stock Summary
Top 10 Correlated ETFs
In the News
Better Therapeutics, Inc. (BTTX) Q2 2023 Earnings Call Transcript
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and CEO Diane Gomez - Chief Commercial Officer Mark Berman - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Keay Nakae - Chardan Rahul Rakhit - LifeSci Capital Operator Good day and thank you for standing by, and welcome to the Better Therapeutics' Second Quarter 2023 Update Call. At this time all participants are in a listen-only mode.
Better Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 09, 2023
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its second quarter 2023 financial results after the market closes on Wednesday, August 09, 2023. Management will host a conference call and webcast to provide a business update at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 09, 2023. To access the conference call, please register at: https://re.
Why Is Better Therapeutics (BTTX) Stock Up 39% Today?
Better Therapeutics (NASDAQ: BTTX ) stock is taking off on Tuesday as investors react to approval from the FDA for a Type 2 diabetes treatment. This covers AspyreRx, which is a prescription-only digital therapeutic treatment for patients 18 and older with Type 2 diabetes.
Better Therapeutics, Inc. (BTTX) Q1 2023 Earnings Call Transcript
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Mark Heinen - CFO Frank Karbe - President and CEO Diane Gomez - Chief Commercial Officer Mark Berman - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Lucas Romanski - TD Cowen Keay Nakae - Chardan Keay Rahul Rakhit - LifeSci Capital Operator Good morning and thank you for standing by, and welcome to the Better Therapeutics' First Quarter 2023 Conference Call. At this time all participants are in a listen-only mode.
Better Therapeutics, Inc. (BTTX) Moves to Buy: Rationale Behind the Upgrade
Better Therapeutics, Inc. (BTTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Better Therapeutics, Inc. (BTTX) Q3 2022 - Earnings Call Transcript
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and Chief Executive Officer Mark Berman - Chief Medical Officer Diane Gómez-Thinnes - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Rahul Rakhit - LifeSci Capital Keay Nakae - Chardan Operator Good afternoon, and welcome to the Better Therapeutics Third Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Better Therapeutics, Inc. (BTTX) CEO Frank Karbe on Q2 2022 Results - Earnings Call Transcript
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Mark Heinen – Chief Financial Officer Frank Karbe – President and Chief Executive Officer Mark Berman – Chief Medical Officer Conference Call Participants Thomas Flaten – Lake Street Capital Rahul Rakhit – LifeSci Capital Keay Nakae – Chardan Operator Good morning, and welcome to the Better Therapeutics Second Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Why Is Better Therapeutics (BTTX) Stock Up 27% Today?
Source: Minerva Studio / Shutterstock.com Better Therapeutics (NASDAQ: BTTX ) stock is rocketing higher on Thursday as investors react to results from a Phase 2 clinical trial. This Phase 2 study saw Better Therapeutics using BT-001 to treat type 2 diabetes.
Better Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 Diabetes
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will host a conference call and webcast on Thursday, July 28, 2022, at 8:30 a.m. ET to review the results from the pivotal clinical trial of BT-001 after 180 days of treatment for type 2 diabetes. Members of the Better Therapeutics managemen
3 Penny Stocks That Have Huge Catalysts Ahead
While you don't want to play with money you can't afford to lose, these penny stocks might bring home the goods for the bold. The post 3 Penny Stocks That Have Huge Catalysts Ahead appeared first on InvestorPlace.
BTTX Financial details
BTTX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
|Revenue per share||0||0||0||0|
|Net income per share||-0.25||-0.27||-3.11||-1.69|
|Operating cash flow per share||-0.26||-0.24||-2.37||-1.23|
|Free cash flow per share||-0.38||-0.34||-2.46||-1.28|
|Cash per share||0.03||0.01||3.12||0.67|
|Book value per share||-0.03||-0.29||2.83||-0.04|
|Tangible book value per share||-0.16||-0.52||2.44||-0.2|
|Share holders equity per share||-0.03||-0.29||2.83||-0.04|
|Interest debt per share||0.21||0.03||0.75||0.69|
|Price to sales ratio||13.11K||29.5K||0||0|
|EV to sales||13.35K||29.56K||0||0|
|Enterprise value over EBITDA||-42.14||-37.85||-0.96||-0.66|
|EV to operating cash flow||-38.64||-40.96||-0.95||-0.87|
|EV to free cash flow||-26.83||-29.28||-0.92||-0.84|
|Free cash flow yield||-0.04||-0.03||-0.53||-1.15|
|Debt to equity||-8.26||-0.09||0.26||-16.55|
|Debt to assets||1.02||0.1||0.19||0.65|
|Net debt to EBITDA||-0.74||-0.08||1.02||0.02|
|Sales general and administrative to revenue||122.06||306.88||0||0|
|Research and developement to revenue||127.22||372.25||0||0|
|Intangibles to total assets||0.67||0.87||0.1||0.17|
|Capex to operating cash flow||0.44||0.4||0.03||0.04|
|Capex to revenue||-152||-288.13||0||0|
|Capex to depreciation||-38||-30.73||-0.66||-0.43|
|Stock based compensation to revenue||4.67||29.13||0||0|
|Return on tangible assets||-3.59||-7.68||-0.88||-2.09|
|Tangible asset value||-3.87M||-12.31M||31.64M||-4.79M|
|Net current asset value||-4.5M||-12.68M||31.01M||-5.4M|
|Days sales outstanding||0||0||0||0|
|Days payables outstanding||136.16||275.09||0||0|
|Days of inventory on hand||0||0||0||0|
|Capex per share||-0.12||-0.1||-0.08||-0.05|
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
|Revenue per share||0||0||0||0||0|
|Net income per share||-0.48||-0.37||-0.39||-0.24||-0.15|
|Operating cash flow per share||-0.3||-0.27||-0.37||-0.16||-0.15|
|Free cash flow per share||-0.31||-0.28||-0.39||-0.18||-0.15|
|Cash per share||0.94||0.66||0.25||0.2||0.17|
|Book value per share||0.31||-0.04||-0.41||-0.35||-0.26|
|Tangible book value per share||0.13||-0.2||-0.57||-0.46||-0.33|
|Share holders equity per share||0.31||-0.04||-0.41||-0.35||-0.26|
|Interest debt per share||0.64||0.65||0.63||0.47||0.36|
|Price to sales ratio||0||0||0||0||0|
|EV to sales||0||0||0||0||0|
|Enterprise value over EBITDA||-3.32||-3.06||-2.82||-6.7||-4.08|
|EV to operating cash flow||-4.87||-4.02||-2.89||-8.2||-3.67|
|EV to free cash flow||-4.63||-3.81||-2.72||-7.46||-3.66|
|Free cash flow yield||-0.18||-0.25||-0.55||-0.17||-0.42|
|Debt to equity||2.04||-16.55||-1.48||-1.32||-1.44|
|Debt to assets||0.52||0.65||1.14||1.22||1.33|
|Net debt to EBITDA||0.73||0.1||-0.95||-1.29||-1.44|
|Sales general and administrative to revenue||0||0||0||0||0|
|Research and developement to revenue||0||0||0||0||0|
|Intangibles to total assets||0.15||0.17||0.29||0.31||0.26|
|Capex to operating cash flow||0.05||0.06||0.06||0.1||0|
|Capex to revenue||0||0||0||0||0|
|Capex to depreciation||-0.52||-0.5||-0.69||-0.63||-0.01|
|Stock based compensation to revenue||0||0||0||0||0|
|Return on tangible assets||-0.47||-0.46||-1.03||-0.95||-0.74|
|Tangible asset value||3.13M||-4.79M||-13.59M||-14.37M||-12.73M|
|Net current asset value||2.52M||-5.4M||-14.2M||-14.97M||-13.31M|
|Days sales outstanding||0||0||0||0||0|
|Days payables outstanding||0||0||0||0||0|
|Days of inventory on hand||0||0||0||0||0|
|Capex per share||-0.02||-0.02||-0.02||-0.02||0|
BTTX Frequently Asked Questions
What is Better Therapeutics, Inc. stock symbol ?
Better Therapeutics, Inc. is a US stock , located in San francisco of Ca and trading under the symbol BTTX
What is Better Therapeutics, Inc. stock quote today ?
Better Therapeutics, Inc. stock price is $0.2316 today.
Is Better Therapeutics, Inc. stock public?
Yes, Better Therapeutics, Inc. is a publicly traded company.